Short-term perioperative treatment with ambroxol reduces pulmonary complications and hospital costs after pulmonary lobectomy: a randomized trial

European Journal of Cardio-thoracic Surgery

Volumn 35, Issue 3, 2009, Pages 469-473

  Refai, Majed ^a   Brunelli, Alessandro ^a   Xiumé, Francesco ^a   Salati, Michele ^a   Sciarra, Valeria ^a   Socci, Laura ^a   Di Nunzio, Luca ^a   Sabbatini, Armando ^a  

^a Azienda Ospedaliera Umberto I   (Italy)

Author keywords

Ambroxol; Non small cell lung cancer; Postoperative complications; Pulmonary lobectomy

Indexed keywords

AMBROXOL; PLACEBO;

ADULT; AGED; ARTICLE; ATELECTASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HOSPITAL COST; HUMAN; LENGTH OF STAY; LUNG CANCER; LUNG EDEMA; LUNG LOBECTOMY; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SHORT COURSE THERAPY;

AGED; AMBROXOL; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; LENGTH OF STAY; LUNG NEOPLASMS; MALE; PERIOPERATIVE CARE; PNEUMONECTOMY; POSTOPERATIVE COMPLICATIONS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY SURFACTANTS; TREATMENT OUTCOME;

EID: 60849121065     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2008.11.015     Document Type: Article

References (17)

1. Nici L. Preoperative and postoperative pulmonary rehabilitation in lung cancer patients. Thorac Surg Clin 18 (2008) 39-43
2. Robertson B. Pharmacological stimulation of surfactant secretion and surfactant replacement. Eur J Respir Dis 67 (1985) 63-70
3. Elemer G., and Kapanci Y. Morphological approach to surfactant secretion in the lungs with particular references to ambroxol. Prog Respir Res 15 (1981) 234-239
4. Olivieri D., Marsico S.A., and Del Donno M. Improvement of mucociliary transport in smokers by mucolytics. Eur J Respir Dis 66 (1985) 142-145
5. Moher D., Shulz K.F., and Altman D.G. The consort statement: revised recommendations for improving the quality of reports of parallel group randomized trials. BMC Med Res Methodol 1 (2001) 2 10.1186/1471-2288-1-2
6. Colice G.L., Shafazand S., Griffin J.P., Keenan R., and Bolliger C.T. Physiologic evaluation of the patient with lung cancer considered for resectional surgery. Chest 132 (2007) 161-177
7. Brunelli A., Xiume F., Al Refai M., Salati M., Marasco R., and Sabbatini A. Risk-adjusted morbidity, mortality and failure-to-rescue models for internal provider profiling after major lung resection. Interact Cardiovasc Thorac Surg 5 (2006) 92-96
8. Harpole D.H., DeCamp M.M., Daley J., Hur K., Oprian C.A., Henderson W.G., and Khuri S.F. Participants in the National Veterans Affairs Surgical Quality Improvement Program. Prognostic models of thirty-day mortality and morbidity after major pulmonary resection. J Thorac Cardiovasc Surg 117 (1999) 969-979
9. Ferguson M.K., and Durkin A.E. A comparison of three scoring systems for predicting complications after major lung resection. Eur J Cardiothorac Surg 23 (2003) 35-42
10. Hawgood S. Surfactant: composition, structure and metabolism. In: Crystal R.G., and West J.B. (Eds). The lung: scientific foundations (1999), Raven Press, New York 247-261
11. Morton N.S. Pulmonary surfactant: physiology, pharmacology and clinical uses. Br J Hosp Med 42 (1989) 52-58
12. Jablonka S., Ledwozyw A., Jablonka A., and Jurko C. Effect of ambroxol on surfactant lipids in patients after resection of pulmonary tissue. Pneumonol Pol 57 (1989) 357-362
13. Nowak D., Antczk A., Krol M., Bialasiewicz P., and Pietras T. Antioxidant properties of ambroxol. Free Radic Biol Med 16 (1994) 517-522
14. Gibbs B.F., Schmutzler W., Vollrath I.B., Brosthardt P., Wolff H.H., and Zwadloklarwasser G. Ambroxol inhibits release of histamine, leukotiens and cytokines from human leukocytes and mast cells. Inflamm Res 48 (1999) 86-93
15. Wiemeyer J.C. Influence of ambroxol on the broncopulmonary level of antibiotics. Arzneimittelforschny 31 (1981) 974-976
16. Romanini B.M., Sandri M.G., Tosi M., Mezzetti M., and Mazzetti A. Ambroxol for prophylaxis and treatment of bronchopulmonary complications after chest surgery. Int J Clin Pharmacol Res 6 (1986) 123-127
17. Fegiz G. Prevention by ambroxol of broncopulmonary complications after upper abdominal surgery: double-blind Italian multicenter clinical study versus placebo. Lung 69 (1991) 69-76